key: cord-0837341-od581czx
authors: Yao, Jasper Seth; Paguio, Joseph Alexander; Dee, Edward Christopher; Tan, Hanna Clementine; Moulick, Achintya; Milazzo, Carmelo; Jurado, Jerry; Della Penna, Nicolás; Celi, Leo Anthony
title: The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study
date: 2020-07-22
journal: Chest
DOI: 10.1016/j.chest.2020.06.082
sha: de2df7fb535b3b1343e1dbf8396677fdba31433e
doc_id: 837341
cord_uid: od581czx

nan

Introduction: Zinc is an investigational agent against coronavirus disease-2019 (COVID-19) and has known preventative and therapeutic roles in other infections. [1] [2] [3] Zinc deficiency is associated with lower survival among older patients with pneumonia and predisposes to other viral infections. 3 Established risk factors for critical COVID-19, including older age, diabetes mellitus, and cardiovascular disease are also associated with zinc deficiency. 2 The antiviral and immunomodulatory effects of zinc have made it a candidate against SARS-CoV2 infection. [2] [3] [4] Zinc may decrease the activity of the angiotensin converting enzyme 2, the receptor for SARS-CoV-2. Zinc T-cell modulation may downregulate the "cytokine storm" associated with severe COVID-19. 2, 4 These properties underlie the speculated efficacy of chloroquine, a zinc ionophore, and the derivative hydroxychloroquine, which are investigational agents in the worldwide SOLIDARITY trial. 2, 5, 6 Furthermore, chloroquine may increase cellular zinc uptake, suggesting therapeutic benefit from the combination of the two agents. 4 Despite zinc's low risk of adverse effects, zinc's role in the management of COVID-19 must be supported by clinical data. 7 Therefore we investigated the role of zinc among hospitalized patients with COVID-19.

In this single-institution retrospective study, we assessed the survival of hospitalized COVID-19 patients treated with versus without zinc sulfate. This study was conducted in accordance with the amended Declaration of Helsinki. This study's protocol was approved and was granted a waiver of informed consent by the hospital board on April 15, 2020 based on its retrospective design and the lack of identifying information to be published, collected, or analyzed.

Data of all patients with COVID-19 (n=242) admitted at the Hoboken University Medical Center until April 11, 2020 were retrospectively collected on April 21, 2020. COVID-19 was confirmed in all patients using quantitative real time RT-PCR for SARS-CoV-2 RNA. Clinical severity was stratified based on WHO guidelines according to clinical, radiographic, and laboratory information from the first 24 hours of admission. 8 The primary outcome was days from admission to in-hospital mortality. Data for patients who did not meet the primary outcome were censored on April 21, 2020.

Our primary analysis explored the causal association between zinc therapy and the survival of hospitalized patients with COVID-19. Inverse probability weighting (IPW) and a censorship model derived an effect estimate of zinc therapy on survival using the parameter the average treatment effect on the treated (ATET). The lack of sufficient overlap or the positive probability of assignment to each treatment level precluded the estimation of the average treatment effect (ATE).

Multivariable logistic regression modeled the propensity to receive zinc by assigning weights to variables which may influence a clinician's decision to administer zinc or to established predictors of mortality. These included age, sex, race, the presence of heart disease or COPD, and clinical severity on admission. 9 Survival analysis with a Weibull censorship distribution model used covariates in the propensity model and potentially efficacious treatments with relevant between-group differences (lopinavir/ritonavir, systemic corticosteroids, interleukin-6 receptor inhibitors, and therapeutic anticoagulation). To explore the additive effect of zinc therapy on various therapies, we performed subgroup analyses among patients who received hydroxychloroquine, lopinavir/ritonavir, steroids, and interleukin-6 receptor inhibitors. Chisquared test for balance assessed whether the distribution of covariates did not vary across treatment levels.

Secondary analysis using multivariable Cox regression with IPW for zinc therapy further assessed the association between zinc therapy and the primary outcome. Zinc therapy and nine other covariates were chosen to avoid overfitting the model (Table 2b) . Analyses (two-sided α=0.05) were performed using Stata/IC 16.1 (StatCorp, CollegeStation, TX).

Results: Of 242 patients, 81.0% received zinc sulfate at a total daily dose of 440mg (100mg elemental zinc). The median age of patients who received zinc was 65 years (IQR 53-77) while that of the control group was 71 years (IQR 58-84, P=0.07); 86 (43.9%) were female in the zinc group, compared to 18 (39.1%) among controls (P=0.6). In the zinc group, 40 (20.4%) had mild disease, 106 (54.1%) had severe disease, and 50 (25.5%) had critical disease. Among controls, 14 (30.4%), 21 (45.7%), and 11 (23.9%) had mild, severe, and critical disease respectively (P=0.3). Baseline clinical and treatment characteristics are summarized in Table 1 .

In the zinc group, 73 (37.2%) patients met the primary outcome, compared to 21 (45.7%) in the control group. In our primary analysis, the effect estimate of zinc therapy was an additional 0.84 days (ATET, 95%CI -1.51-3.20, P=0.48, Table 2a ) of survival. However, this finding was imprecise. Subgroup analyses of severe and critical patients and of patients who received various therapies yielded results which were not statistically significant (Table 2a) . Postestimation Chi-squared test for balance did not reject the null hypothesis that the IPW model balanced covariates between treatment levels (P=0.59).

On multivariate Cox regression with IPW, zinc sulfate was not significantly associated with a change in risk of in-hospital mortality (aHR 0.66, 95%CI 0.41-1.07, P=0.09, Table 2b ). Older age, male sex, and higher clinical severity were significantly associated with an increased risk of in-hospital mortality (Table  2b) . Use of interleukin-6 receptor inhibitors was associated with reduced mortality (Table 2b) .

Discussion: Our analyses demonstrate the lack of a causal association between zinc and the survival of hospitalized patients with COVID-19. Similarly, subgroup analyses stratified by severity or additional therapies did not yield significant causal associations. Given this study's observational design, our findings must not be used to rule in or rule out the clinical benefit of zinc in the management of COVID-19. In addition, given the short period of observation, the effect estimate provides only a signal for a treatment effect, or the lack thereof, and must not be interpreted as the absolute number of days of survival among the treated. 10 Instead, our analyses may be used by prospective trials to determine the sample size necessary to assess survival benefit or may galvanize investigation using other outcomes of interest.

Our analyses may reduce the effects of confounders and selection bias in non-randomized data. 10 Our findings showing an increased mortality risk among older patients, males, and those with higher admission severity are consistent with those of previous literature and support the use of our methodology. 9 Future studies should look into the efficacy of interleukin-6 receptor inhibitors, which in this cohort was associated with lower in-hospital mortality.

This study is limited by its retrospective nature and the possibility of residual confounding. Given the single-center design, the sample size, and the larger proportion of patients given zinc sulfate, we are unable to rule out the possibility that the study was not powered to detect a small effect size--a limitation that motivated us to employ ATET estimation to investigate the effect of zinc on COVID-19. Prospective randomized trials are needed to establish the utility of zinc in the management of COVID-19. Therapeutic anticoagulation 38 (19.4) 4 (8.7) IQR: interquartile range, BMI: body mass index, COPD: chronic obstructive pulmonary disease † Clinical severity was stratified based on clinical, radiographic, and laboratory information from the first 24 hours of admission. Patients with critical disease were those who developed ARDS, septic shock, or multiorgan failure, or those who required mechanical ventilation or ICU admission. Patients were classified as having severe disease if their oxygen saturation as measured by pulse oximetry (SpO2) on room air was 93% or below, if they required oxygen supplementation, or if their respiratory rate was 30 breaths per minute or higher without meeting any of the criteria for critical disease. Hospitalized patients were classified as having mild disease if their SpO2 was 94% and above on room air or if they did not require oxygen supplementation, while not meeting any of the criteria for severe or critical disease. 

Zinc and respiratory tract infections: Perspectives for COVID-19 (Review)

Enhancing immunity in viral infections, with special emphasis on COVID-19: A review

Can Zn Be a Critical Element in COVID-19 Treatment?

Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients

Zinc: An essential micronutrient

Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Control of confounding and reporting of results in causal inference studies